ArticleThe mental health clinician2026
Failed transition to buprenorphine extended-release injection from high-dose methadone.
Article in The mental health clinician, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Symptoms of opioid withdrawal with buprenorphine inductions pose significant challenges when trying to transition a patient from a full agonist opioid. There are numerous strategies to reduce the risk including traditional induction, microdosing, and macrodosing. Whereas there is an abundance of literature on successful strategies, there is limited literature on risk factors that identify those who are likely to fail transition to buprenorphine and should be cautioned. We present a case of a 43-year-old male on high-dose methadone who was rapidly transitioned to buprenorphine. He experienced significant withdrawal symptoms, resulting in hospitalization, multiple relapses, and suicidal ideation. He was ultimately transitioned back to methadone and restabilized. The primary factors likely resulting in this treatment failure are high-dose opioid use prior to transition, rapid transition, and patient reluctance to transition at time of buprenorphine initiation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.